A multi-gene panel beyond BRCA1/BRCA2 to identify new breast cancer-predisposing mutations by a picodroplet PCR followed by a next-generation sequencing strategy: a pilot study

Marcella Nunziato, Maria Valeria Esposito, Flavio Starnone, Maria Angela Diroma, Alessandra Calabrese, Valentina Del Monaco, Pasqualina Buono, Giuseppe Frasci, Gerardo Botti, Massimiliano D'Aiuto, Francesco Salvatore, Valeria D'Argenio

Research output: Contribution to journalArticle

Abstract

By analyzing multiple gene panels, next-generation sequencing is more effective than conventional procedures in identifying disease-related mutations that are useful for clinical decision-making. Here, we aimed to test the efficacy of an 84 genes customized-panel in BRCA1 and BRCA2 mutation-negative patients. Twenty-four patients were enrolled in this study. DNA libraries were prepared using a picodroplet PCR-based approach and sequenced with the MiSeq System. Highly putative pathogenic mutations were identified in genes other than the commonly tested BRCA1/2: 2 pathogenic mutations one in TP53 and one in MUTYH; 2 missense variants in MSH6 and ATM, respectively; 2 frameshift variants in KLLN, and ATAD2, respectively; an intronic variant in ANPEP, and 3 not functionally known variants (a frameshift variant in ATM a nonsense variant in ATM and a missense variant in NFE2L2). Our results show that this molecular screening will increase diagnostic sensitivity leading to a better risk assessment in breast cancer patients and their families. This strategy could also reveal genes that have a higher penetrance for breast and ovarian cancers by matching gene mutation with familial and clinical data, thereby increasing information about hereditary breast and ovarian cancer genetics and improving cancer prevention measures or therapeutic approaches.

LanguageEnglish
JournalAnalytica Chimica Acta
DOIs
Publication statusPublished - 2019

Fingerprint

mutation
cancer
Genes
airborne thematic mapper
Breast Neoplasms
Automatic teller machines
Polymerase Chain Reaction
Mutation
gene
Ovarian Neoplasms
Penetrance
Neoplasm Genes
Gene Library
Risk assessment
Screening
risk assessment
Decision making
decision making
DNA
Neoplasms

Keywords

  • Cancer risk
  • Gene panel testing
  • Germinal predisposing mutations
  • Hereditary breast and ovarian cancer
  • Next-generation sequencing
  • Picodroplet PCR

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Environmental Chemistry
  • Spectroscopy

Cite this

A multi-gene panel beyond BRCA1/BRCA2 to identify new breast cancer-predisposing mutations by a picodroplet PCR followed by a next-generation sequencing strategy : a pilot study. / Nunziato, Marcella; Esposito, Maria Valeria; Starnone, Flavio; Diroma, Maria Angela; Calabrese, Alessandra; Del Monaco, Valentina; Buono, Pasqualina; Frasci, Giuseppe; Botti, Gerardo; D'Aiuto, Massimiliano; Salvatore, Francesco; D'Argenio, Valeria.

In: Analytica Chimica Acta, 2019.

Research output: Contribution to journalArticle

@article{220a429c7fc64f69bc6e101268f0d05f,
title = "A multi-gene panel beyond BRCA1/BRCA2 to identify new breast cancer-predisposing mutations by a picodroplet PCR followed by a next-generation sequencing strategy: a pilot study",
abstract = "By analyzing multiple gene panels, next-generation sequencing is more effective than conventional procedures in identifying disease-related mutations that are useful for clinical decision-making. Here, we aimed to test the efficacy of an 84 genes customized-panel in BRCA1 and BRCA2 mutation-negative patients. Twenty-four patients were enrolled in this study. DNA libraries were prepared using a picodroplet PCR-based approach and sequenced with the MiSeq System. Highly putative pathogenic mutations were identified in genes other than the commonly tested BRCA1/2: 2 pathogenic mutations one in TP53 and one in MUTYH; 2 missense variants in MSH6 and ATM, respectively; 2 frameshift variants in KLLN, and ATAD2, respectively; an intronic variant in ANPEP, and 3 not functionally known variants (a frameshift variant in ATM a nonsense variant in ATM and a missense variant in NFE2L2). Our results show that this molecular screening will increase diagnostic sensitivity leading to a better risk assessment in breast cancer patients and their families. This strategy could also reveal genes that have a higher penetrance for breast and ovarian cancers by matching gene mutation with familial and clinical data, thereby increasing information about hereditary breast and ovarian cancer genetics and improving cancer prevention measures or therapeutic approaches.",
keywords = "Cancer risk, Gene panel testing, Germinal predisposing mutations, Hereditary breast and ovarian cancer, Next-generation sequencing, Picodroplet PCR",
author = "Marcella Nunziato and Esposito, {Maria Valeria} and Flavio Starnone and Diroma, {Maria Angela} and Alessandra Calabrese and {Del Monaco}, Valentina and Pasqualina Buono and Giuseppe Frasci and Gerardo Botti and Massimiliano D'Aiuto and Francesco Salvatore and Valeria D'Argenio",
year = "2019",
doi = "10.1016/j.aca.2018.09.032",
language = "English",
journal = "Analytica Chimica Acta",
issn = "0003-2670",
publisher = "Elsevier",

}

TY - JOUR

T1 - A multi-gene panel beyond BRCA1/BRCA2 to identify new breast cancer-predisposing mutations by a picodroplet PCR followed by a next-generation sequencing strategy

T2 - Analytica Chimica Acta

AU - Nunziato, Marcella

AU - Esposito, Maria Valeria

AU - Starnone, Flavio

AU - Diroma, Maria Angela

AU - Calabrese, Alessandra

AU - Del Monaco, Valentina

AU - Buono, Pasqualina

AU - Frasci, Giuseppe

AU - Botti, Gerardo

AU - D'Aiuto, Massimiliano

AU - Salvatore, Francesco

AU - D'Argenio, Valeria

PY - 2019

Y1 - 2019

N2 - By analyzing multiple gene panels, next-generation sequencing is more effective than conventional procedures in identifying disease-related mutations that are useful for clinical decision-making. Here, we aimed to test the efficacy of an 84 genes customized-panel in BRCA1 and BRCA2 mutation-negative patients. Twenty-four patients were enrolled in this study. DNA libraries were prepared using a picodroplet PCR-based approach and sequenced with the MiSeq System. Highly putative pathogenic mutations were identified in genes other than the commonly tested BRCA1/2: 2 pathogenic mutations one in TP53 and one in MUTYH; 2 missense variants in MSH6 and ATM, respectively; 2 frameshift variants in KLLN, and ATAD2, respectively; an intronic variant in ANPEP, and 3 not functionally known variants (a frameshift variant in ATM a nonsense variant in ATM and a missense variant in NFE2L2). Our results show that this molecular screening will increase diagnostic sensitivity leading to a better risk assessment in breast cancer patients and their families. This strategy could also reveal genes that have a higher penetrance for breast and ovarian cancers by matching gene mutation with familial and clinical data, thereby increasing information about hereditary breast and ovarian cancer genetics and improving cancer prevention measures or therapeutic approaches.

AB - By analyzing multiple gene panels, next-generation sequencing is more effective than conventional procedures in identifying disease-related mutations that are useful for clinical decision-making. Here, we aimed to test the efficacy of an 84 genes customized-panel in BRCA1 and BRCA2 mutation-negative patients. Twenty-four patients were enrolled in this study. DNA libraries were prepared using a picodroplet PCR-based approach and sequenced with the MiSeq System. Highly putative pathogenic mutations were identified in genes other than the commonly tested BRCA1/2: 2 pathogenic mutations one in TP53 and one in MUTYH; 2 missense variants in MSH6 and ATM, respectively; 2 frameshift variants in KLLN, and ATAD2, respectively; an intronic variant in ANPEP, and 3 not functionally known variants (a frameshift variant in ATM a nonsense variant in ATM and a missense variant in NFE2L2). Our results show that this molecular screening will increase diagnostic sensitivity leading to a better risk assessment in breast cancer patients and their families. This strategy could also reveal genes that have a higher penetrance for breast and ovarian cancers by matching gene mutation with familial and clinical data, thereby increasing information about hereditary breast and ovarian cancer genetics and improving cancer prevention measures or therapeutic approaches.

KW - Cancer risk

KW - Gene panel testing

KW - Germinal predisposing mutations

KW - Hereditary breast and ovarian cancer

KW - Next-generation sequencing

KW - Picodroplet PCR

UR - http://www.scopus.com/inward/record.url?scp=85054040536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054040536&partnerID=8YFLogxK

U2 - 10.1016/j.aca.2018.09.032

DO - 10.1016/j.aca.2018.09.032

M3 - Article

JO - Analytica Chimica Acta

JF - Analytica Chimica Acta

SN - 0003-2670

ER -